Answers are grounded in this paper and cite their sources.
Background Anthracene and chalcone-based derivatives possess diverse pharmacological properties; however, comprehensive studies integrating their synthesis, structural characterization, quantum chemical investigation, molecular docking, molecular dynamics (MD) simulation, ADMET evaluation, and experimental anticancer assessment targeting Carbonic Anhydrase II (CA-II) remain limited. This study aimed to synthesize and comprehensively evaluate a novel anthracene–chalcone derivative, ( E )-1-(Anthracen-9-yl)-3-(4-chlorophenyl)prop-2-en-1-one (PCPO), as a potential CA-II-targeted anticancer lead compound. Methods PCPO was synthesized via Claisen–Schmidt condensation with a 90% yield and characterized using FT-IR and NMR spectroscopy. Density functional theory (DFT) calculations, including geometry optimization, natural bond orbital (NBO), frontier molecular orbital (FMO), molecular electrostatic potential (MEP), Mulliken charge, intrinsic reaction coordinate (IRC), UV–Vis, electronic circular dichroism (ECD), and density of states (DOS) analyses, were performed to investigate its structural and electronic properties. Molecular docking against CA-II (PDB ID: 6VJ3) was carried out, followed by a 100 ns molecular dynamics simulation to evaluate complex stability. Drug-likeness and pharmacokinetic properties were predicted using ADMET analysis. The in vitro anticancer activity was assessed by MTT assay, and the IC₅₀ value was compared with that of doxorubicin. Results DFT calculations confirmed a planar and highly conjugated molecular structure with a C O bond length of 1.258 Å. NBO analysis revealed significant π→π*, σ→σ*, and n→π* interactions contributing to electronic stabilization, while FMO analysis showed an energy gap of 5.4081 eV, indicating moderate chemical reactivity. MEP and Mulliken charge analyses identified O27 as the most electron-rich region and Cl38 as the electron-deficient center. The IRC analysis confirmed a single transition state connecting reactants and products, and DOS analysis suggested semiconducting behavior with an approximate band gap of 0.8 eV. Molecular docking demonstrated a binding affinity of −9.0 kcal/mol, which was stronger than that of the native ligand (−7.5 kcal/mol) and tamoxifen (−7.2 kcal/mol), supported by hydrogen bonding with GLN92 and hydrophobic interactions involving VAL135, PRO202, and LEU198. The 100 ns MD simulation demonstrated a stable protein–ligand complex with low RMSD and RMSF fluctuations throughout the simulation. ADMET prediction indicated acceptable drug-like characteristics, including a molecular weight of 342.08 Da and favorable membrane permeability, although high lipophilicity (logP = 6.028) and limited aqueous solubility were observed. MTT cytotoxicity evaluation against A549 human lung cancer cells demonstrated concentration-dependent antiproliferative activity, with an IC₅₀ value of 12.6 µg/mL, comparable to that of doxorubicin (13.8 µg/mL). Conclusions The integrated experimental and computational analyses demonstrate that PCPO possesses favorable structural stability, electronic characteristics, strong CA-II binding affinity, stable protein–ligand interactions, and promising in vitro antiproliferative activity. These findings support PCPO as a promising lead scaffold for the further development and optimization of Carbonic Anhydrase II-targeted anticancer agents, while additional in vivo and mechanistic studies are required to validate its therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Rajaraman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: